articleThe Lancet OncologyFeb 13, 2025Closed access

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

LELouise EmmettSSShalini SubramaniamMCMegan CrumbakerAMAnthony M. JoshuaSSShahneen Sandhu

The Kinghorn Cancer Centre · Garvan Institute of Medical Research · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

52
total citations
FWCI
59.09
Percentile
100%
References
21
Citations per year

Authors

89

Topics & keywords

Topics
Keywords
  • Enzalutamide
  • Medicine
  • Prostate cancer
  • Oncology
  • Open label
  • Overall survival
  • Internal medicine
  • Quality of life (healthcare)
UN Sustainable Development Goals
  • Zero hunger
No related works found for this paper.

Funding